$2.0986
0.0786[3.89%]
Last update: 6:30PM Get Real Time Here
ProQR Therapeutics
(NASDAQ:PRQR)ProQR Therapeutics Stock (NASDAQ:PRQR), Analyst Ratings, Price Targets, Predictions
ProQR Therapeutics NV has a consensus price target of $6.29, established from looking at the 30 latest analyst ratings. The last 3 analyst ratings were released from Citigroup, HC Wainwright & Co., and Chardan Capital on April 18, 2024, March 14, 2024, and March 14, 2024. With an average price target of $3.17 between Citigroup, HC Wainwright & Co., and Chardan Capital, there's an implied 50.89% upside for ProQR Therapeutics NV from these 3 analyst ratings.
Analyst Firms Making Recommendations1
Citigroup
HC Wainwright & Co.
Chardan Capital
Raymond James
Cantor Fitzgerald
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for ProQR Therapeutics
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 04/18/2024 | PRQR | Buy Now | ProQR Therapeutics | $2.10 | -4.7% | Citigroup | Yigal Nochomovitz | $1.8 → $2 | Maintains | Neutral | Get Alert |
| 03/14/2024 | PRQR | Buy Now | ProQR Therapeutics | $2.10 | 138.25% | HC Wainwright & Co. | Andrew Fein | → $5 | Reiterates | Buy → Buy | Get Alert |
| 03/14/2024 | PRQR | Buy Now | ProQR Therapeutics | $2.10 | 19.13% | Chardan Capital | Keay Nakae | $2 → $2.5 | Maintains | Buy | Get Alert |
| 11/08/2023 | PRQR | Buy Now | ProQR Therapeutics | $2.10 | 90.6% | Raymond James | Steven Seedhouse | $5 → $4 | Maintains | Outperform | Get Alert |
| 11/08/2023 | PRQR | Buy Now | ProQR Therapeutics | $2.10 | -4.7% | Chardan Capital | Keay Nakae | → $2 | Upgrade | Neutral → Buy | Get Alert |
| 09/18/2023 | PRQR | Buy Now | ProQR Therapeutics | $2.10 | -14.23% | Citigroup | Yigal Nochomovitz | $2.1 → $1.8 | Maintains | Neutral | Get Alert |
| 08/07/2023 | PRQR | Buy Now | ProQR Therapeutics | $2.10 | 138.25% | HC Wainwright & Co. | Andrew Fein | → $5 | Reiterates | Buy → Buy | Get Alert |
| 08/04/2023 | PRQR | Buy Now | ProQR Therapeutics | $2.10 | -4.7% | Chardan Capital | Keay Nakae | → $2 | Reiterates | Neutral → Neutral | Get Alert |
| 05/26/2023 | PRQR | Buy Now | ProQR Therapeutics | $2.10 | 0.07% | Citigroup | Yigal Nochomovitz | $2.25 → $2.1 | Maintains | Neutral | Get Alert |
| 05/17/2023 | PRQR | Buy Now | ProQR Therapeutics | $2.10 | 114.43% | Cantor Fitzgerald | Jennifer Kim | $5 → $4.5 | Maintains | Overweight | Get Alert |
| 05/17/2023 | PRQR | Buy Now | ProQR Therapeutics | $2.10 | 185.9% | JMP Securities | Jonathan Wolleben | → $6 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 05/17/2023 | PRQR | Buy Now | ProQR Therapeutics | $2.10 | 138.25% | HC Wainwright & Co. | Andrew Fein | → $5 | Reiterates | Buy → Buy | Get Alert |
| 03/30/2023 | PRQR | Buy Now | ProQR Therapeutics | $2.10 | 185.9% | JMP Securities | Jonathan Wolleben | → $6 | Reiterates | → Market Outperform | Get Alert |
| 03/30/2023 | PRQR | Buy Now | ProQR Therapeutics | $2.10 | 138.25% | HC Wainwright & Co. | Andrew Fein | $1.5 → $5 | Maintains | Buy | Get Alert |
| 12/23/2022 | PRQR | Buy Now | ProQR Therapeutics | $2.10 | 138.25% | Raymond James | Steven Seedhouse | $2 → $5 | Maintains | Outperform | Get Alert |
| 12/22/2022 | PRQR | Buy Now | ProQR Therapeutics | $2.10 | 138.25% | Cantor Fitzgerald | Jennifer Kim | $0.8 → $5 | Upgrade | Neutral → Overweight | Get Alert |
| 08/15/2022 | PRQR | Buy Now | ProQR Therapeutics | $2.10 | -28.52% | HC Wainwright & Co. | Andrew Fein | $2 → $1.5 | Maintains | Buy | Get Alert |
| 08/12/2022 | PRQR | Buy Now | ProQR Therapeutics | $2.10 | — | Chardan Capital | Keay Nakae | — | Downgrade | Buy → Neutral | Get Alert |
| 08/12/2022 | PRQR | Buy Now | ProQR Therapeutics | $2.10 | -4.7% | Raymond James | Steven Seedhouse | → $2 | Upgrade | Market Perform → Outperform | Get Alert |
FAQ
What is the target price for ProQR Therapeutics (PRQR)?
The latest price target for ProQR Therapeutics (NASDAQ: PRQR) was reported by Citigroup on April 18, 2024. The analyst firm set a price target for $2.00 expecting PRQR to fall to within 12 months (a possible -4.70% downside). 12 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for ProQR Therapeutics (PRQR)?
The latest analyst rating for ProQR Therapeutics (NASDAQ: PRQR) was provided by Citigroup, and ProQR Therapeutics maintained their neutral rating.
When was the last upgrade for ProQR Therapeutics (PRQR)?
The last upgrade for ProQR Therapeutics NV happened on November 8, 2023 when Chardan Capital raised their price target to $2. Chardan Capital previously had a neutral for ProQR Therapeutics NV.
When was the last downgrade for ProQR Therapeutics (PRQR)?
The last downgrade for ProQR Therapeutics NV happened on August 12, 2022 when Chardan Capital changed their price target from N/A to N/A for ProQR Therapeutics NV.
When is the next analyst rating going to be posted or updated for ProQR Therapeutics (PRQR)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of ProQR Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for ProQR Therapeutics was filed on April 18, 2024 so you should expect the next rating to be made available sometime around April 18, 2025.
Is the Analyst Rating ProQR Therapeutics (PRQR) correct?
While ratings are subjective and will change, the latest ProQR Therapeutics (PRQR) rating was a maintained with a price target of $1.80 to $2.00. The current price ProQR Therapeutics (PRQR) is trading at is $2.10, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.